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Abstract
Extracellular vesicles (EVs) present in the urine are mainly released from cells of the nephron and can therefore provide
information on kidney function. We here evaluated the presence of vesicles expressing the progenitor marker CD133 in the
urine of normal subjects and of patients undergoing renal transplant. We found that EV expressing CD133 were present in
the urine of normal subjects, but not of patients with end stage renal disease. The first day after transplant, urinary CD133+
EVs were present at low levels, to increase thereafter (at day 7). Urinary CD133+ EVs significantly increased in patients with
slow graft function in respect to those with early graft function. In patients with a severe pre-transplant vascular damage of
the graft, CD133+ EVs did not increase at day 7. At variance, the levels of EVs expressing the renal exosomal marker CD24 did
not vary in the urine of patients with end stage renal disease or in transplanted patients in respect to controls. Sorted
CD133+ EVs were found to express glomerular and proximal tubular markers. These data indicate that urinary CD133+ EVs
are continuously released during the homeostatic turnover of the nephron and may provide information on its function or
regenerative potential.
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Introduction
Extracellular vesicles (EVs) are circular fragments of membrane
released from the endosomal compartment or shed from the
surface membranes of most cell types [1]. EVs express surface
receptors and contain proteins and extracellular RNA shared in
great part with the cell of origin and their presence has been
identified in all biological fluids [1,2]. In the urine, EVs are
considered to mainly derive from cells of the nephron, with a
minimal contribution of the lower urinary collecting system cells
[3]. Indeed, proteomic analysis of urinary EVs identified
membrane and cytosolic proteins, which have characteristics of
renal tubule epithelial cells of different nephron segments and of
podocytes [3,4]. Urinary EVs can therefore provide quantitative
and qualitative information on the state of the kidney [5], thus
suggesting their use as biomarkers in renal pathology.
After kidney transplantation from deceased donor, ischemia-
reperfusion injury of the graft causes renal tubular epithelial cell
necrosis and apoptosis leading to loss of organ function [6,7]. A
slow or delayed graft function may affect approximately 25% of
transplant recipients, causing a significant increase in early
transplant-related morbidity and a long term decrease of graft
survival [6]. The current approach to clinical management of
episodes of renal dysfunction during the first six months after
transplantation is mainly based on the results of a percutaneous
allograft biopsy [7]. In addition, advances in non-invasive immune
monitoring for rejection, such as measurements of signs of cellular
immune response, are currently available [8]. However, non
invasive tools for evaluation of renal damage and regeneration
would be required to guide effective therapeutic interventions.
Intrinsic mechanisms of tissue repair and regeneration occur in
the mammalian kidney to re-acquire functionality after ischemic,
toxic or inflammatory insults [9]. Recent evidence indicates that
cells with characteristics of progenitors, expressing the stem cell
marker CD133 and lacking differentiation markers, are present in
different segments of the human nephron, being localized in the
Bowman capsule of glomeruli, in proximal tubules as well as in
inner medullary papilla region including Henle’s loop and S3 limb
segment [10–12]. In addition, CD133+ cells in the cortex increase
in number after acute renal damage, suggesting their role in renal
repair after injury [13]. In particular, the number of CD133+ cells
was reported to increase in tubules of transplanted patients
undergoing delayed graft function as a result of acute renal injury
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[13], as well as of patients with proteinuric glomerular diseases
[14,15].
Somatic stem and precursor cells of nervous and hematopoietic
origin have been shown to release CD133-carrying EVs [16,17]
and their level in the spinocerebral fluids associated to pathological
conditions [18,19]. We therefore reasoned that CD133+ cells along
the nephron could similarly release CD133-carrying EVs and that
the presence of these EVs in the urine may provide information on
the physiopathological state of the kidney or on its regenerative
ability. Indeed, CD133-carrying EVs were previously reported in
the urine of normal subjects [20]. In the present study, we aimed
to better characterize the urinary CD133+ EVs and to assess their
levels in normal subjects and in patients with chronic and acute
renal dysfunction. In particular, CD133+ EVs were evaluated in
patients with end stage renal disease and in kidney transplanted
patients with early or slow graft function, at different days after
transplantation.
Materials and Methods
Ethical statement
i) Urine samples: the study was conducted using urine samples
from normal human volunteers and transplanted patients.
Approval from the San Giovanni Battista Hospital Review Board
was obtained, and written informed consent was given by each
participant. ii) HLA typing sera from multiparous women: HLA
typing sera were obtained from multiparous women by the HLA
typing laboratory of our hospital following approval of the San
Giovanni Battista Hospital Review Board and stored in an
anonymous fashion. All participants gave written consent for their
samples to be used in research. iii) kidneys from deceased donors:
the evaluation of vascular lesions was performed on protocol
biopsies of kidneys from deceased donors prior to transplantation.
All organ donor next of kin gave written consent for use of the
donor samples in research (as part of the overall protocol and
consent for organ donation), as approved by the Regional
Transplant Institutional Board.
Patients
Urine samples were obtained from normal human volunteers
and transplanted patients. Levels of CD133+ EVs were compared
in transplanted patients (n = 25), in age-matched controls (n = 20)
and in end stage renal disease (ESRD) patients with residual
diuresis (n = 5). All patient information is presented in Table 1. In
addition, in selected experiments, urinary EVs were obtained from
urine pooled from normal subjects (n = 10, age: 2863, M/F: 4/6).
Evs isolation and count
Urinary EVs from transplanted patients were collected from
80 ml of urine drained by a vescical catheter, from a 6-hours
collection, at the first (D1) and the seventh (D7) day after the
transplant. In selected patients (n = 6), urine was also collected
after 30 days. Urine from controls (control normal subjects) and
ESRD patients was obtained from 80 ml of the second morning
urine or of a 6-hours collection. In addition urine was collected
from normal subjects after an oral water load. After voiding, a
water load of 20 ml/kg was given orally for 30 minutes. Urine was
collected for 6 hours [21].
Urine was centrifuged at 2500 rpm for 15 minutes to pellet cells
and Tamm-Horsfall protein. The supernatant was supplemented
with protease inhibitor (Sigma) and NaN3 10 mM (Fluka), filtered
through a 0.8 mM filter (Millipore) and then ultracentrifuged at
100.000 g for 1 hour at 4uC. The pellet was resuspended in RPMI
(Sigma) and 1% DMSO (Sigma) was added to allow freezing
storage in 280uC until use.
EV quantification. For cytofluorimetric and Western Blot
analysis, samples were quantified through a proteic Bradford
assay. Urinary EVs were also analysed by nanoparticle tracking
analysis (NTA), using the NanoSight LM10 system (NanoSight
Ltd, Amesbury, UK), configured with a 405 nm laser and a high
sensitivity digital camera system (OrcaFlash2.8, Hamamatsu
C11440, NanoSight Ltd) as previously described [22]. Briefly,
EVs coming from 80 ml of urine were resuspended in 100 ml of
vesicle-free physiologic solution (Fresenius Kabi, Runcorn, UK).
Each sample was then diluted 1:1000 in the same solution. For this
analysis, a monochromatic laser beam at 405 nm was applied to
the diluted suspension of EVs. For each sample, three videos of
30 seconds duration were recorded and number of particles/ml
and mean size was averaged. NTA post-acquisition settings were
optimized and kept constant between samples, and each video was
then analysed to give the mean, mode, and median vesicle size
together with an estimation of the concentration.
Sorting of CD133+ fraction
Sorting of CD133+ EVs was performed on urine pools obtained
from the second morning urine of normal subjects. CD133+ EVs
were isolated by magnetic cell sorting, using the CD133
MicroBead Kit applied to the MACS system (Miltenyi Biotec,
Auburn, CA). Briefly, urinary EVs were collected from a total
volume of 200 ml of urine. The relative pellet, obtained after the
100.000 g ultracentrifugation, was resuspended in 100 ml of
ultracentrifuged vesicle-free MACS Buffer, then 100 ml of FcR
Blocking Reagent and 100 ml of CD133 MicroBeads were added.
This mix was incubated for 30 minutes at 4uC. Hereafter 250 ml of
vesicle-free MACS buffer was added to stop the coupling reaction
of the antibody to the EVs. The final sample volume of 550 ml was
totally applied onto the LS-column for the EVs separation as
recommended by the manufacturer’s instructions. CD1332 EVs,
finally present in a buffer suspension of 9 ml, and the CD133+
EVs, present in a buffer suspension of 5 ml, were then collected
through a further 100.000 g centrifuge. Both CD133+ and
CD1332 EVs pellets were analyzed using Western blot analysis.
For nanoparticle tracking analysis, CD133+ EVs were sorted using
an indirect labelling that allows removal magnetic beads with the
APC multisorting kit (Miltenyi). Briefly, pelleted EVs were stained
with the APC conjugated CD133 mAb (1:20 dilution, 10 minutes
at 4uC), ultracentrifuged, and then sorted with the APC-multi-
sorting kit following the manufacture’s instructions.
Cytofluorimetric analysis
Flow cytometry analysis was performed with a FACSCalibur
machine using CellQuest software (Becton Dickinson Bioscience
Pharmingen, Franklyn Lake, NJ, USA). As EVs are too small for
FACScan analysis, we bound EVs to surfactant-free white
aldehyde/sulfate latex beads 4% w/v, 4 mm diameter (Molecular
Probes, Invitrogen) [23]. We incubated 5 ml beads with 15 mg EVs
for 10–15 minutes at RT and then overnight at 4uC in a final
volume of 1 ml PBS-BSA 0.5%. Then the adsorbed EVs were
divided in different vials and incubated with antibodies diluted
1:50, for 15 minutes at 4uC. The adsorbed EVs were then washed
and analyzed with a FACSCalibur and CellQuest software. Flow
cytometry was performed using anti-human monoclonal antibod-
ies (MAbs): APC-conjugated CD133 (AC133; Miltenyi, Auburn,
CA, USA); FITC conjugated CD24, PE-conjugated CD9, PE-
conjugated CD81 (Becton Dickinson) and anti-Rab5 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Comparison of urinary
EVs among groups was performed by evaluating the relative
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Table 1. Characteristics of the transplanted patients, ESRD patients and normal subjects in the study.
Early graf function (n=13) Slow graft function (n =12)
RECIPIENTS
Age, years 53.8614.1 56.1612.1 ns
Sex, (M/F) 6/7 11/2
Cause of chronic
kidney disease
Unknown, 3; Chronic
pyelonephritis, 2; APKD, 2;
Gn, 5; nephroangiosclerosis, 1.
Unknown, 1; Chronic pyelonephritis,
3; Gn, 5; nephroangiosclerosis, 1;
diabetic nephropathy, 2;
hemolytic-uremic syndrome, 1.
Prior treatment
Hemodialysis, No (%) 11 (84) 10 (77) ns
Peritoneal dialysis,
No (%)
2 (15.3) 3 (23) ns
Time on dialysis
(months)
51.1648.9 71.56126 ns
Retransplant, No (%) 3 (23) 3 (23) ns
Panel reactive
Antibody .20%, No (%)
2 (15.3) 1(7.7) ns
$4 HLA mismatches,
No (%)
12 (100%) 11 (84%) ns
LD/DD 0/13 1/12 ns
Cold ischemia time, h 14.565 14.165.5 ns
Induction ID, No. (%)
Basiliximab 13 (100) 11 (84) ns
Rituximab 0 1 (7) ns
No induction 0 1 (7) ns
Maintenance ID,
No. (%)
Tacrolimus 13 (100) 12 (92) ns
Mycophenolate mofetil 11 (84) 12 (92) ns
Steroid 13 (100) 13 (100) ns
Urine 24-h volume (ml)
Before transplantation 5776701 7006730 ns
day 1 post-transplant 287562799 11106989 p= 0.02
day 7 post-transplant 370661098 388162025 ns
GFR ns
day 1 post-transplant 14.266.5 12.864.3 ns
day 7 post-transplant 45.2623 14.365.4 p = 0.0001
DONORS
Age, years 60.9620.5 67.3611 ns
ECD, No (%) 11 (84%) 11 (84%) ns
GFR (ml/min) 98.8649 84.3617 ns
Hypertension, No (%) 8 (61.5) 9 (69.2) ns
Diabetes, No (%) 3 (23) 1 (7.7)
Histological score
Glomerular sclerosis 1.260.4 0.960.3 p = 0.04
Tubular atrophy 0.260.4 0.160.3 ns
Interstitial fibrosis 0.560.5 0.360.5 ns
Arterial and arteriolar
narrowing
1.260.4 0.960.5 ns
Final score 361 2.260.9 p = 0.04
ESRD patients (n=5)
Age, yrs 54.4617,6
Sex, (M/F) 1/4
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PLOS ONE | www.plosone.org 3 August 2014 | Volume 9 | Issue 8 | e104490
amount of EVs positive for a selected marker in respect to all EVs,
in conditions where the same quantity of EVs was tested (15 mg
protein, corresponding roughly to 161012 urinary EVs/mg
protein, as evaluated by Bradford protein analysis and NTA,
respectively). This protein amount was selected by preliminary
experiments using different amounts of EVs (from 1 to 50 mg,) that
showed no increase in CD133 level at concentration higher than
15 mg (Figure S1). To assess vesicle binding to latex beads,
CD133+ or CD1332 EVs were labelled with Vibrant Dil cell-
labeling solution (Molecular Probes by Life Techonologies) and
processed for fluorescence analysis. No difference was observed in
CD133+ or CD1332 EV fluorescence (Figure S1).
Western Blot
For protein analysis, both the CD133+ and the CD1332
fractions of EVs were lysed at 4uC for 30 minutes in RIPA buffer
(20 nM Tris-HCl, 150 nM NaCl, 1% deoxycholate, 0.1% SDS,
1% Triton X-100, pH 7.8) supplemented with protease and
phosphatase inhibitors cocktail and PMSF (Sigma). When the
protein concentration was lower than 2 mg/ml a protocol was
used to precipitate, and then concentrate, 10 mg of proteins [24].
Briefly, the volume corresponding to 10 mg was brought to 250 ml
with deionized water, and then 800 ml of Methanol, 200 ml of
Chloroform and dH2O were added. The mix was strongly
vortexed and centrifuged at 12000 rpm for 2 minutes. The upper
phase was removed and 600 ml of MetOH was added. After a
centrifuge the upper part was removed and the pellet was left to
dry under the hood. The remaining dried pellet was resuspended
in a proper volume of Laemmli Buffer and the sample was loaded
onto the gel. Aliquots of the cell lysates containing 10 mg proteins,
as determined by the Bradford method, were run on 10%
acrylamide gel SDS-PAGE under reducing conditions. The
transfer of proteins onto a PVDF membrane was performed in a
7 minutes transfer program of the iBlotTM Dry Blotting System
(Life Technology). The following primary antibodies were used:
CD133/1 (clones AC133 and W6B3C1) (Miltenyi), rabbit
polyclonal CD133 (Abcam) both at 1:500 dilution; CD81, CD9
and CD63 (all from Becton Dickinson) at 1:200 dilution; Megalin,
Table 1. Cont.
Early graf function (n=13) Slow graft function (n =12)
Cause of chronic kidney
disease
APKD, 2; Unknown, 1;
nephroangiosclerosis, 1;
Cisplatin-induced
nephropathy, 1
Urine 24-hours volume
(ml)
17806705
CONTROL SUBJECTS
(n=20)
Age, yrs 51.8617.1
Sex, (M/F) 11/9
ECD: expanded criteria donors according to Crystal City Meeting criteria [35]. GFR: glomerular filtration rate. Histological score: performed on pretransplant biopsies
according to a semiquantitative method [25]. APKD: adult polycystic kidney disease; Gn: glomerulonephritis; LD: living donor; DD: deceased donor. ID:
immunosuppressive therapy. ESRD: end-stage kidney disease. Continuous variables are express as mean 6 SD.
doi:10.1371/journal.pone.0104490.t001
Figure 1. Characterization of normal urinary EVs. Panel A. NanoSight analysis of samples prepared from the urine of normal subjects showing
their size distribution profile. A peak at 151 nm was observed. Panel B and C. Representative images of the expression of exosome markers by
urinary EVs by cytofluorimetric (B) and Western Blot analysis (C). Cytofluorimetric histograms show marker detection (grey area) and isotypic control
(dark line). Five different preparations were tested with similar results.
doi:10.1371/journal.pone.0104490.g001
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Aquaporin-1 (AQ1) and Aquaporin-2 (AQ2) at 1:100 dilution;
Aminopeptidase A and CD2 Associated protein (CD2AP) (all from
Santa Cruz Biotechnology) at 1:200 dilution.
HLA typing sera. Sera from multiparous women were
obtained by the HLA typing laboratory of our hospital. Sera
characterized to contain antibodies directed against the HLA class
I antigens of the donors were used in order to distinguish the origin
of the extracellular vesicles. Typing sera were used at 1:50 dilution
in Western Blot experiments. The use of an irrelevant serum gave
no signal (data not shown).
Histological evaluation of vascular lesions. Briefly, kid-
neys from deceased donors underwent a protocol biopsy prior to
transplantation in order to quantify the severity of tissue damage
according to the histological score proposed by Remuzzi et al [25].
All specimens were evaluated by the same renal pathologist.
Specifically, vascular lesions defined as arterial and arteriolar
narrowing were scored as follow: 0 absent (n = 7), 1 increased wall
thickness but to a degree that is less than the diameter of the lumen
(n = 15), 2 wall thickness that is equal or slightly greater to the
diameter of the lumen (n = 3), 3 wall thickness that far exceeds the
diameter of the lumen with extreme luminal narrowing or
occlusion (n = 0).
Statistical methods
Statistical analysis was performed with SPSS (IBM SPSS
Statistics, vers. 12.0.0). Continuous variables are presented as
median (min–max), according to their distribution. The difference
between groups of these variables was analyzed with Mann-
Whitney, Wilcoxon or Kruskal-Wallis test.
Categorical variables are presented as fraction and Pearson’s or
for small samples Fisher’s exact test was employed to compare
Figure 2. Expression of CD133 by urinary vesicles. Panel A. Representative cytofluorimetric and Western Blot (clone AC133) images of the
expression of CD133 by urinary vesicles of normal subjects. The cytofluorimetric histogram shows CD133 detection (grey area) and isotypic control
(dark line). Panel B. Scatter and fluorescence dot plots showing similar CD133+ EV levels in normal urine of a second morning minction or of a 6-
hours collection. Plots are representative of three experiments with similar results. Panel C. Representative image of CD133 detection in CD133+ and
CD1332 sorted EVs (clone W6B3C1). Panel D and E. Representative images and quantification of the expression of different nephron markers by the
total urinary EVs and by CD133+ and CD1332 sorted EVs. Data are mean 6 SD of at least three different experiments and report the marker
expression in the sorted fractions normalized on the expression in the Total EVs. AminoP.: Aminopeptidase A, AQ: Aquaporin, CD2AP: CD2 Associated
protein. * = p,0.05.
doi:10.1371/journal.pone.0104490.g002
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groups. The odds ratios (OR) were used as a measure of relative
risk. Significance level for all tests was set at p,0.05.
Results
Detection and characterization of CD133+ urinary EV in
normal subjects
EVs were isolated from urine obtained from normal subjects
using a two-step differential centrifugation protocol based on a first
low-speed centrifugation, followed by filtration trough a 0.8 mm
filter to remove cells, cellular debris and apoptotic bodies. The
supernatant was subsequently ultracentrifuged at 100,000 g for
1 h to sediment urinary vesicles. Urinary EVs showed a
heterogenic size, as evaluated by NanoSight analysis, with a mean
peak of 151 nm (Fig. 1A).
Cytofluorimetric analysis of the EVs using latex beads showed
presence of typical exosome markers such as CD9, CD81 and
Rab5, and of the renal vesicle marker CD24 [26] (Fig. 1B).
Figure 1C shows Western Blot analysis of EVs expressing the
tetraspanins CD9, CD63 and CD81. We focused our attention on
CD133, a stem cell marker expressed in the kidney by progenitors
cells [10–12] and previously described in the urinary EVs [20]. We
found that CD133+ EVs were detectable at high levels in the urine
of normal subjects using cytofluorimetric assay (Fig. 2A). No
difference was observed in the levels of CD133+ EV according to
the urine collection protocol, as the same results were obtained in
the second-morning urine or in a 6 h collection urine of the same
subject (Fig. 2B). By Western Blot analysis, CD133 was detected
using the stem/progenitor specific antibody against the AC133
isoform, and its molecular weight was compatible with the
glycosylated isoform (120 kDa) confirming that EVs expressed
the stem/progenitor specific isoform of CD133 [17,20] (Fig. 2A).
To further characterize the possible origin of CD133+ EVs from
different nephron segments, we sorted CD133+ EVs and
compared the expression of typical nephron markers in the
CD133 positive and negative fractions. Sorting CD133+ EVs using
magnetic beads provided a specific enrichment of vesicles
expressing CD133, that was undetectable in the negative fraction
(Fig. 2C). As shown in Fig. 2D and E, the CD133+ fraction
expressed CD63 at low levels. The proximal tubular markers AQ1
and Megalin, but not Aminopeptidase A were expressed by
CD133+ EVs. In addition, the glomerular marker CD2AP was
highly expressed by CD133+ EVs in respect to the negative
fraction whereas the collecting duct marker AQ2 was only present
in the negative fraction (Fig. 2D and E). These data suggest that
CD133+ EVs may have a glomerular and proximal tubular origin.
CD133+ and CD1332 EVs did not differ in size, as evaluated by
nanoparticle track analysis (Figure S1). Moreover, labelled
CD1332 and CD133+ EVs showed similar binding to latex beads,
as proved by similar fluorescence intensity (Figure S1).
We next assessed whether the presence of CD133+ EVs within
urine might be influenced by parameters such as the urinary flow
and urine concentration. After an acute water load, urine (6 h
collection) was diluted in respect to a regular water uptake of the
same subject (6 h collection); urinary creatinine: 42.367.2 g/L vs
119.6624 mg/dL). The levels of CD133+ EVs did not signifi-
cantly vary in the same subject according to urine dilution (mean
variation 3.866.7%, n = 3).
CD133+ urinary Evs are decreased in transplanted
patients with SGF
We next evaluated the presence of CD133+ EVs in the urine of
transplanted patients at day 1 and 7 after transplant. As soon as 1
day after transplant, EVs were present in the urine and the
Figure 3. Characterization of urinary EVs in transplanted patients. Urinary EVs were obtained from patients (n = 25) undergoing renal
transplant. Panel A. Mean number of EVs/day in the urine of transplanted patients were similar at day 1 and 7 after transplant, counted as described
in Material and Methods. Data are mean6 SD of all samples. Panel B and C. Characterization of EVs showing expression of CD9 and CD81 exosome
markers and NanoSight analysis of size distribution profile. Similar results were obtained for samples from all transplanted patients at day 1 and 7.
Panel D. Representative western blot analysis showing the donor origin of the extracellular vesicle using typing sera containing antibodies directed
against HLA class I antigens of the donor not shared by the recipient, at 1 and 7 days after transplant. In the table are reported the HLA typing of the
recipient and the donor and the HLA-antigen recognized by the typing serum (TORP1262). HLA-B5 (bold) is present in the donor and not in the
recipient. Three patients were tested with similar results.
doi:10.1371/journal.pone.0104490.g003
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production evaluated as EV number/die did not significantly vary
within the first 7 days (Fig. 3A). EVs from transplanted patients
expressed the exosome markers CD9 and CD81 and a mean size
of 179 nm (Fig. 3B and C). To check whether EVs derived from
the transplanted kidney rather than from the native kidney or from
the lower urinary tract, EVs were stained with anti-HLA Class I
Abs recognizing the donor specific antigen isoforms. As shown in
Fig. 3D, a band detecting donor specific HLA Class I was present
both at 1 and 7 days after transplant.
We evaluated the relative percentage of EVs expressing CD133
using a cytofluorimetric analysis (Fig. 4B). The expression of
CD24, a marker of urinary vesicles [26], was used as control. First,
to assess whether CD133+ EVs specifically derived by a
functioning kidney, we analyzed CD133+ EVs in ESRD patients
with a residual diuresis. No CD133+ EVs were detected in the
urine of ESRD patients. The level of CD24 was maintained
constant in healthy subjects and ESRD patients, indicating a
specific loss of CD133+ EVs in patients with impairment of the
renal function.
CD133+ EVs were present in patients undergoing transplant in
the first day. However, the CD133+ EV levels were significantly
lower than those of healthy subjects matched for age and sex with
the kidney donors. Levels of CD133+ EVs increased 7 days after
transplant to levels statistically not different from control subjects
(Fig. 4A and Fig. 5). In contrast, no significant difference was
observed in the levels of CD24+ EVs, suggesting the absence of
variation in vesicle production by the kidney. Evaluation of
CD133+ EV levels at 30 days after transplant in 6 patients did not
show significant variation in respect to day 7 (Fig. 4A).
Figure 4. CD24+ and CD133+ EVs in the urine of normal subjects, ESRD and transplanted patients. Panel A. Levels of urinary CD24+ and
CD133+ EVs in normal subjects (H), ESRD patients with residual diuresis and transplanted patients at day 1, 7 or 30 after transplant (D1, D7 and D30,
respectively). A significant reduction of CD133+ EVs but not of CD24+ EVs was observed in ESRD and transplanted patients at day 1. Data are
expressed as % positive beads and are mean 6 SD of all samples. Panel B and C. Representative cytofluorimetric histograms (B) and median values
(C) of CD24+ and CD133+ EV levels in the urine of patients with EGF (n = 13) and SGF (n = 12) at day 1 and 7 after transplant. Urinary CD133+ EVs but
not CD24+ EVs were lower in EGF patients at day 1, and significantly increased at day 7. Statistical analysis was performed as described in the
Materials and methods section. * = p,0.05.
doi:10.1371/journal.pone.0104490.g004
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PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e104490
Transplanted patients were retrospectively divided in respect to
kidney function into patients with EGF or SGF, the latter defined
as .3 mg/dl creatinine at day 3 [24]. Interestingly, at day 1 the
CD133+ EVs were lower in SGF than in EGF patients, although it
did not reach a statistical significance (p = 0.08). At day 7, the
increase in CD133+ EVs levels was significant only in patients with
SGF. Levels of CD24, used as control of the presence of urinary
vesicles, did not significantly vary in the different conditions
(Fig. 4B and C).
The increase of CD133+ EVs levels from day 1 to day 7 was not
related to different urine dilution, as urine concentration did not
significantly vary in the first 7 days post-transplant (urinary
creatinine concentration: 3465 mg/dL at day 1vs 29.868 mg/dL
at day 7), as recently reported [27]. Moreover, the increase was
not dependent on a parallel increase in the glomerular filtration, as
the glomerular filtration rate increased from day 1 to day 7 only in
EGF but not in SGF patients (Table 1).
CD133+ urinary Evs correlate with the severity of the
vascular damage in pre-transplanted kidneys
In addition, when patients were divided according to the graft
vascular lesions, evaluated as indicated in the material and
methods [25], CD133+ EV levels, and not CD24+ EV levels,
showed a different increase within time (Fig. 6). In particular,
patients with vascular score 2 did not show a recovery of the
CD133+ EVs levels at day 7 after transplant. No correlation of
CD133+ EVs was found with other parameters such as ischemia
time, introduction of calcineurin inhibitors, HLA mismatch or pre-
transplant diuresis (Table 2).
Figure 5. Detection of CD133+ EVs in transplanted patients. Panel A and B. Representative dot plots showing the gating strategy of latex
bead-conjugated EVs (A) and the fluorescence detection of isotype or CD133 on EVs from a transplanted patients at day 1 or 7.
doi:10.1371/journal.pone.0104490.g005
Table 2. Correlation of CD133+ EVs and patients’ clinical parameters.
No CD133+ EVs T1 p* CD133+ EVs T7 p*
Ischemia (h) ,15 12 4.38 [0.49–11.88] 0.936 8.41[0.00–56.03] 0.503
.15 13 6.13 [0.28–31.82] 8.00 [0.00–68.68]
CNI introduction ab initio 7 5.37 [0.51–11.88] 0.836 11.23 [1.48–62.29] 0.389
at Crt,2.5 18 5.86 [0.28–31.82] 7.93 [0.00–68.68]
HLA Mismatches ,4 12 5.48 [0.28–31.82] 0.852 4.24 [0.00–68.68] 0.087
.4 13 6.13 [0.49–12.88] 8.69 [1.48–62.29]
Pre-transplant diuresis .1 L 11 6.65 [0.28–31.82] 0.085 11.77 [0.34–68.68] 0.166
,1 L 14 2.81 [0.49–12.88] 6.51 [0.00–62.26]
No correlation was found among CD133+ EVs and ischemia time, introduction of calcineurin inhibitors (CNI), HLA mismatches, and pre-transplant diuresis. Data are
expressed are median [min-max], p* =Mann-Withney test.
doi:10.1371/journal.pone.0104490.t002
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Discussion
In the present study, we show that CD133+ expressing EVs are
present in the urine of normal subjects, but not of patients with
ESRD. In the urine of transplanted patients CD133+ EVs were
present at low levels the first day after transplant, to increase
thereafter (at day 7). In particular, at day 1 the level of CD133+
EVs was lower in patients showing a slow graft function in respect
to those with early graft function, then it significantly increased at
day 7. Finally, in patients with a severe pre-transplant vascular
damage of the graft, CD133+ EVs did not increase at day 7. No
significant variation was observed in the presence of CD24+ EVs
in patients with ESRD or in transplanted patients.
EVs present in urine could derive both from the cell surface or
from intracellular multivescicolar bodies and could be accordingly
classified as microvesicles or exosomes, respectively. However, a
clear difference based on vesicle markers or dimension is at present
of debate [28] and, in the present study, we studied the entire
population of EVs present in the urine. The presence of CD133+
EVs in the urine of normal subject and polycystic kidney disease
patients was previously reported using Western Blot and
immunogold analysis [20,29]. CD133+/CD632 EVs with a large
size (400 nm) were described to be released into body fluids from
microvilli of epithelial cells [20]. Other studies reported the
biogenesis of CD133+ EVs by multivesicular bodies and their
release as CD63+ exosomes [17,30]. The results of our study,
showing the presence of CD63 at low levels in CD133+ sorted EVs
by Western Blot analysis, suggests that both type of vesicles may be
present in urine. The proteomic analysis of urinary EVs previously
identified proteins from renal epithelia extending from the
glomerular podocytes through the proximal tubules to collecting
ducts [3], suggesting that all nephron segments may contribute to
their generation. At variance, the origin of CD133+ EVs appeared
more restricted to glomeruli and proximal tubules based on the
expression of surface markers on CD133+ sorted EVs. Further
information in support of the renal origin of CD133+ EVs is
provided by their detection immediately after transplantation.
Since patients with end stage renal disease did not release CD133+
EVs, the CD133+ EVs found in the urine of transplanted patients
the first day after transplant are most likely released by the graft.
This is also confirmed by the presence of graft-specific HLA Class
I antigens by urinary EVs of transplanted patients. The possible
function of the CD133+ EVs in renal physiology still remains to be
investigated. It could be however speculated that CD133+ EVs
may interact with cells of the nephron, as described for CD133+
EVs released in the urine of polycystic kidney disease patients [29].
In the nervous system, the shedding of CD133+ EVs from the
cell surface was regarded as a mechanism of cell differentiation
and of neural specification [16]. Similarly, CD133+ EVs are shed
by CD133+ hematopoietic stem cells during the process of cell
differentiation [17]. Our data show that CD133+ EVs are
continuously released by renal cells suggesting the involvement
of CD133+ progenitors in the homeostatic turnover of the
nephron. The reduction of urinary CD133+ EV levels but not of
CD24+ EVs in end stage renal disease indicates that these vesicles
are only released by functioning renal tissue, suggesting an
exhaustion of the progenitor activity that parallels the loss of
kidney function.
It could be therefore speculated that the number of CD133+
EVs may reflect the activity of CD133+ cells in the kidney, as
CD133+ EVs were lower in patients with a slow graft function in
respect to those with early graft function. In addition, in these
latter patients, CD133+ EVs significantly increased after 7 days,
possibly underlying that their presence correlates with the graft
recovery after tissue damage. Moreover in the same patients the
number of CD133+ EVs at day 7 reached levels not significantly
different in comparison with normal subjects. Our results parallel
the data reported by Loverre et al. [13] showing that CD133+ cells
were reduced in renal tissue of pre-transplant delayed graft
function patients in respect to early graft function patients. In
addition, in delayed graft function patients, an increase of
proliferating CD133+ cells was observed 10 days after transplant
[13]. These data may further implicate CD133+ cells in the
regeneration of renal tissue after injury due to cold ischemia and
ischemia-reperfusion, as suggested in several studies [14,15,31]. In
addition, in patients with a severe pre-transplant vascular damage,
we observed the lack of increase in urinary CD133+ EVs at day 7.
Figure 6. Median values of CD24+ and CD133+ EV levels in the urine of transplanted patients at day 1 and 7 after transplant (D1 and
D7), divided according to the graft vascular lesions (VS), as described in Material and methods. No increase in urinary CD133+ EVs was
observed in VS2 patients. Statistical analysis was performed as described in the Materials and methods section. * = p,0.05.
doi:10.1371/journal.pone.0104490.g006
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This may imply an inefficient regeneration in the renal tissue of
patients with high vascular damage. The lack of variations in
CD24+ EVs, used as marker of urinary EVs, indicates that the
observed differences in CD133+ EV release do not reflect
alteration in EV number but rather in the composition of the
vesicle population. Indeed, the relative CD133+ EV levels did not
vary in relation to urine concentration or glomerular filtration
rate.
Previous studies identified that the amount of membrane
particle-associated CD133 was significantly enhanced in patients
with glioblastoma and in epileptic patients as compared to healthy
adults [18,19]. At variance with these studies, evaluating the
amount of CD133 using Western Blot analysis, our study was
based on cytofluorimetric evaluation of CD133+ EVs labeled on
latex beads. This is a common method to analyze the expression of
markers expressed on the EV surface [23]. This method resulted
reliable and highly sensitive. In addition, as the results represent a
relative expression of positive EVs on the total population, it was
not influenced by urine dilution and EV amount in the urine. We
are, however, aware that our data do not represent real
percentages of CD133+ EVs, as the level of positivity is the result
of numerous EVs bound to each bead. These data support the idea
that the analysis of urinary CD133+ EVs may represent a possible
biomarker for tissue injury or for the repair capacity of the
nephron.
The possible use of urinary exosomes as markers of renal
damage has already been proposed. For instance, activating
transcription factor 3 and Wilms tumor 1 were associated with
early tubular and podocyte injury in different experimental models
[32]. Moreover, a reduction in the levels of AQ1 in urinary
exosomes has been associated with renal ischemia–reperfusion
injury in rats [33]. Finally, it has been recently shown that
detection of fetuin-A in urinary EVs is a biomarker of renal injury
in patients developing acute kidney injury [34]. The evaluation of
urinary CD133+ EVs as marker of tubular function and repair
may be of interest in acute renal injury, and it could be possibly
extended to patients with different levels of chronic renal damage.
Taken together, these results suggest that CD133+ EVs may
reflect the activity of CD133+ progenitor cells in renal homeostasis
and may provide information on their regenerative potential after
acute kidney injury.
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